Mechanisms of Resistance to TKI in NSCLC
D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses mechanisms of resistance to TKIs in oncogene-driven non–small cell lung cancer.
D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses mechanisms of resistance to TKIs in oncogene-driven nonsmall cell lung cancer (NSCLC).
Even though osimertinib (Tagrisso) is better in the brain than the other agents in this class, it is not a perfect central nervous system (CNS) drug, Camidge says. It is marketed as a CNS penetrant, but patients still progress on osimertinib. Researchers have to decide if this is a dosing situation with osimertinib or if there are simply better drugs in the future. Studies have looked at adding erlotinib (Tarceva) and gefitinib (Iressa) to treatment, but Camidge notes this works in a petri dish but not in a patient.
Some mechanisms of resistance are understood by thoracic oncologists. For example, some patients withEGFR
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
